Exposure to the meningococcal group B vaccine during a New Zealand mass vaccination campaign was associated with a reduced likelihood of contracting gonorrhoea, compared with unvaccinated people, according to a new study of more than 14,000 people published in The Lancet. This is the first time that a vaccine has shown any protection against gonorrhoea, and may provide a new avenue for vaccine development.

Ed Rybicki’s insight:
Given the rapid development of multiply-resistant strains, this is a really good development.

First vaccine to show protection against gonorrhoea
Source: Virology News

Tagged with:

Comments are closed.